Security
Second Sight Medical Products Inc. Warrants expiring 03/14/2024 · EYESW
EYESWNASDAQWarrantHistorical · closed Aug 30, 2022CIK 1266806Updated Oct 31, 2026
Name history
SECOND SIGHT MEDICAL PRODUCTS INC · through Aug 18, 2022SECOUND SIGHT MEDICAL PRODUCTS INC · through Oct 10, 2003
Current security for this SEC filerVANI · NASDAQ
EYESW price & chart
Historical security
This listing closed Aug 30, 2022. Live provider charts are shown only for current listings.
Current security: VANI
About the company
Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. For more information, please visit: www.vivani.com.
In the news
No coverage from other publishers is available.
Recent filings
Regulation FD Disclosure
Items 7.01
Regulation FD Disclosure
Items 7.01, 9.01
424B5 filing
Regulation FD Disclosure
Items 7.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 25,046,000Source | 42,896,000Source | 41,639,000Source | 28,905,000Source | 48,224,000Source | 42,353,000Source | 35,452,000Source | 53,788,000Source | 39,393,000Source | 41,561,000Source | 45,797,000Source | 51,130,000Source |
| Property, Plant and Equipment, NetUSD | 2,726,000Source | 1,644,000Source | 2,850,000Source | 1,577,000Source | 1,710,000Source | 2,752,000Source | 1,609,000Source | 1,689,000Source | 2,879,000Source | 1,693,000Source | 1,729,000Source | 1,182,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,628,000Source | 19,646,000Source | 19,894,000Source | 6,794,000Source | 24,919,000Source | 19,749,000Source | 13,008,000Source | 29,648,000Source | 16,232,000Source | 18,352,000Source | 20,654,000Source | — |
| Assets, CurrentUSD | 4,175,000Source | 21,399,000Source | 21,635,000Source | 8,715,000Source | 26,337,000Source | 21,548,000Source | 14,850,000Source | 31,502,000Source | 17,898,000Source | 20,442,000Source | 23,062,000Source | 47,528,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 883,000Source | 1,753,000Source | 1,032,000Source | 1,427,000Source | 1,418,000Source | 1,102,000Source | 1,667,000Source | 1,854,000Source | 1,012,000Source | 1,837,000Source | 2,408,000Source | 2,452,000Source |
| Operating Lease, Right-of-Use AssetUSD | 16,784,000Source | 18,383,000Source | 16,169,000Source | 17,146,000Source | 18,801,000Source | 16,616,000Source | 17,523,000Source | 19,212,000Source | 17,230,000Source | 17,957,000Source | 19,616,000Source | 779,000Source |
| Other Assets, NoncurrentUSD | 1,338,000Source | 1,338,000Source | 892,000Source | 1,338,000Source | 1,338,000Source | 1,338,000Source | 1,338,000Source | 1,338,000Source | — | — | 1,338,000Source | 1,366,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 23,737,000Source | 24,564,000Source | 22,672,000Source | 23,995,000Source | 24,400,000Source | 23,268,000Source | 23,828,000Source | 25,078,000Source | 23,663,000Source | 23,951,000Source | 25,036,000Source | 6,822,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 9,000Source | 6,000Source | 6,000Source | 8,000Source | 6,000Source | 5,000Source | 8,000Source | 6,000Source | 5,000Source | 109,050,000Source |
| Additional Paid in CapitalUSD | 143,062,000Source | 134,108,000Source | 180,609,000Source | 140,193,000Source | 133,588,000Source | 174,358,000Source | 139,802,000Source | 133,094,000Source | 164,225,000Source | 139,480,000Source | 119,054,000Source | 8,009,000Source |
| Retained Earnings (Accumulated Deficit)USD | -141,900,000Source | -115,874,000Source | -161,683,000Source | -135,370,000Source | -109,833,000Source | -155,313,000Source | -128,226,000Source | -104,477,000Source | -148,533,000Source | -121,924,000Source | -98,438,000Source | -72,786,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 141,000Source | 92,000Source | 32,000Source | 81,000Source | 63,000Source | 32,000Source | 42,000Source | 88,000Source | 30,000Source | 48,000Source | 140,000Source | 35,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,309,000Source | 18,332,000Source | 18,967,000Source | 4,910,000Source | 23,824,000Source | 19,085,000Source | 11,624,000Source | 28,710,000Source | 15,730,000Source | 17,610,000Source | 20,761,000Source | 44,308,000Source |
| Liabilities and EquityUSD | 25,046,000Source | 42,896,000Source | 41,639,000Source | 28,905,000Source | 48,224,000Source | 42,353,000Source | 35,452,000Source | 53,788,000Source | 39,393,000Source | 41,561,000Source | 45,797,000Source | 51,130,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,830,000Source | 6,270,000Source | 6,659,000Source | 6,716,000Source | 5,784,000Source | 6,775,000Source | 6,199,000Source | 6,138,000Source | 6,602,000Source | 5,986,000Source | 5,723,000Source | 6,822,000Source |
| Operating Lease, Liability, CurrentUSD | 1,386,000Source | 1,385,000Source | 1,843,000Source | 1,337,000Source | 1,420,000Source | 1,782,000Source | 1,311,000Source | 1,434,000Source | 1,794,000Source | 1,348,000Source | 1,383,000Source | 955,000Source |
| Accounts Payable, CurrentUSD | 1,434,000Source | 815,000Source | 1,195,000Source | 1,762,000Source | 645,000Source | 1,465,000Source | 1,004,000Source | 570,000Source | 1,032,000Source | 817,000Source | 542,000Source | 1,177,000Source |
| Operating Lease, Liability, NoncurrentUSD | 16,907,000Source | 18,294,000Source | 16,013,000Source | 17,279,000Source | 18,616,000Source | 16,493,000Source | 17,629,000Source | 18,940,000Source | 17,061,000Source | 17,965,000Source | 19,313,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,978,000Source | 2,024,000Source | 1,629,000Source | 1,586,000Source | 1,660,000Source | 1,504,000Source | 1,859,000Source | 1,953,000Source | 1,736,000Source | 1,803,000Source | 1,727,000Source | 2,358,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 130,000Source | 102,000Source | 424,000Source | 400,000Source | 357,000Source | 381,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 312,000Source | 350,000Source | 1,484,000Source | 1,610,000Source | 1,864,000Source | 1,296,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 433,000Source | 175,000Source | -222,000Source | 248,000Source | -602,000Source | -1,941,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,196,000Source | -5,163,000Source | -24,320,000Source | -20,786,000Source | -23,699,000Source | -18,787,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -3,000Source | -5,000Source | -1,173,000Source | -556,000Source | -887,000Source | -338,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 3,000Source | 5,000Source | 1,173,000Source | 556,000Source | 887,000Source | 338,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 9,714,000Source | -170,000Source | 23,274,000Source | 19,054,000Source | 133,000Source | 63,390,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 3,517,000Source | -5,344,000Source | -2,120,000Source | -2,302,000Source | -24,450,000Source | 44,264,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | 19,690,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 2,000Source | — | 2,000Source | 1,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 276,000Source | 472,000Source | 313,000Source | 391,000Source | 312,000Source | 350,000Source | 1,484,000Source | 1,610,000Source | 1,864,000Source | 1,296,000Source |
| DepreciationUSD | — | — | — | — | 128,000Source | 100,000Source | — | — | 400,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | -60,000Source | -121,000Source | — |
| General and Administrative ExpenseUSD | — | — | 2,206,000Source | 2,106,000Source | 2,418,000Source | 2,703,000Source | 2,427,000Source | 2,340,000Source | 9,430,000Source | 8,932,000Source | 9,997,000Source | 7,072,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,530,000Source | -6,041,000Source | -6,370,000Source | -7,144,000Source | -6,780,000Source | -6,302,000Source | -26,609,000Source | -23,486,000Source | -25,652,000Source | -13,889,000Source |
| Operating ExpensesUSD | — | — | 6,725,000Source | 6,309,000Source | 6,874,000Source | 7,462,000Source | 6,817,000Source | 6,557,000Source | 27,556,000Source | 24,677,000Source | 26,965,000Source | 21,241,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,057,000Source | 1,161,000Source | 949,000Source | 1,173,000Source | 1,158,000Source | 1,173,000Source | 4,532,000Source | 3,999,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | -195,000Source | -262,000Source | 504,000Source | -318,000Source | -167,000Source | -255,000Source | 947,000Source | 1,191,000Source | — | — |
| Other Operating Income (Expense), NetUSD | — | — | 195,000Source | 268,000Source | 504,000Source | 318,000Source | 37,000Source | 255,000Source | — | — | 1,313,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -6,725,000Source | -6,309,000Source | -6,874,000Source | -7,462,000Source | -6,817,000Source | -6,557,000Source | -27,556,000Source | -24,677,000Source | -26,965,000Source | -21,241,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -195,000Source | -262,000Source | 504,000Source | -318,000Source | -167,000Source | -255,000Source | 947,000Source | 1,191,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -26,609,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,530,000Source | -6,041,000Source | -6,370,000Source | -7,144,000Source | -6,780,000Source | -6,302,000Source | -26,609,000Source | -23,486,000Source | -25,652,000Source | -13,889,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.11Source | -0.11Source | -0.07Source | -0.12Source | -0.08Source | -0.11Source | -0.43Source | -0.43Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.11Source | -0.11Source | -0.07Source | -0.12Source | -0.08Source | -0.11Source | -0.43Source | -0.43Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 59,711,000Source | 55,247,000Source | 87,090,000Source | 59,244,000Source | 81,269,000Source | 59,236,000Source | 62,389,000Source | 54,981Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 59,711,000Source | 55,247,000Source | 87,090,000Source | 59,244,000Source | 81,269,000Source | 59,236,000Source | 62,389,000Source | 54,981Source | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 105,000Source | 107,000Source | — | 100,000Source | 130,000Source | 103,000Source | 424,000Source | 408,000Source | 400,000Source | 400,000Source |
| General and Administrative ExpenseUSD | — | — | 2,206,000Source | 2,106,000Source | 2,418,000Source | 2,703,000Source | 2,427,000Source | 2,340,000Source | 9,430,000Source | 8,932,000Source | 9,997,000Source | 7,072,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -24,910,000Source | — | — | — |
| Interest Income, OperatingUSD | — | — | — | — | — | — | — | — | — | — | — | 475,000Source |
| Labor and Related ExpenseUSD | — | — | 2,817,000Source | 2,858,000Source | 2,948,000Source | 2,885,000Source | 3,000,000Source | 2,694,000Source | 11,414,000Source | 11,805,000Source | — | — |
| Operating ExpensesUSD | — | — | 6,725,000Source | 6,309,000Source | 6,874,000Source | 7,462,000Source | 6,817,000Source | 6,557,000Source | 27,556,000Source | 24,677,000Source | 26,965,000Source | 21,241,000Source |
| Operating Lease, ExpenseUSD | — | — | 1,057,000Source | 1,161,000Source | 949,000Source | 1,173,000Source | 1,158,000Source | 1,173,000Source | 4,532,000Source | 3,999,000Source | — | — |
| Other General and Administrative ExpenseUSD | — | — | 290,000Source | 298,000Source | 585,000Source | 327,000Source | 373,000Source | 211,000Source | 1,110,000Source | 806,000Source | 100,000Source | — |
| Other General ExpenseUSD | — | — | — | — | — | — | — | — | 300,000Source | 300,000Source | 300,000Source | 400,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 195,000Source | 268,000Source | 504,000Source | 318,000Source | 37,000Source | 255,000Source | — | — | 1,313,000Source | — |
| Research and Development ExpenseUSD | — | — | 4,519,000Source | 4,203,000Source | 4,456,000Source | 4,759,000Source | 4,390,000Source | 4,217,000Source | 18,126,000Source | 15,745,000Source | 16,968,000Source | 14,169,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — |
Filing attachments
ex991_1.htm · 8-K · 2026-08-13
EX-99.1 7 ex991_1.htm EXHIBIT 99.1 Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 Company entered into non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal™ technology…
Read attachment ↗ex991_1.htm · 8-K · 2026-08-06
EX-99.1 7 ex991_1.htm EXHIBIT 99.1 Exhibit 99.1 Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1™ trial is a Phase 1, randomized, controlled clinical trial design to characterize the safety, tolerability, and pharm…
Read attachment ↗